Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic

Jung Sunwoo,1 Yu Kyong Kim,1 Yewon Choi,1 Kyung-Sang Yu,1 Heesook Nam,2 Young Lag Cho,2 Seonghae Yoon,3 Jae-Yong Chung3 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, 2LegoChem Biosciences, Inc., Daejeon, 3Department of Clin...

Full description

Bibliographic Details
Main Authors: Sunwoo J, Kim YK, Choi Y, Yu KS, Nam H, Cho YL, Yoon S, Chung JY
Format: Article
Language:English
Published: Dove Medical Press 2018-06-01
Series:Drug Design, Development and Therapy
Subjects:
Online Access:https://www.dovepress.com/effect-of-food-on-the-pharmacokinetic-characteristics-of-a-single-oral-peer-reviewed-article-DDDT
_version_ 1818527270415892480
author Sunwoo J
Kim YK
Choi Y
Yu KS
Nam H
Cho YL
Yoon S
Chung JY
author_facet Sunwoo J
Kim YK
Choi Y
Yu KS
Nam H
Cho YL
Yoon S
Chung JY
author_sort Sunwoo J
collection DOAJ
description Jung Sunwoo,1 Yu Kyong Kim,1 Yewon Choi,1 Kyung-Sang Yu,1 Heesook Nam,2 Young Lag Cho,2 Seonghae Yoon,3 Jae-Yong Chung3 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, 2LegoChem Biosciences, Inc., Daejeon, 3Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea Background: LCB01-0371 is a novel oxazolidinone antibiotic that blocks protein production by binding to bacterial 23S ribosomes. This antibiotic is active against Gram-positive bacteria. This study aimed to evaluate the effect of food on the pharmacokinetics (PKs) of LCB01-0371 and evaluate its safety profile.Subjects and methods: A randomized, open-label, two-way crossover study was performed in 18 healthy Korean male subjects. All subjects received a single oral 800 mg dose of LCB01-0371 in each period under fed or fasting condition with a 7-day washout in between. The fed condition was defined as consumption of a meal of 800–1,000 kcal containing ~50% of fat content. Serial blood samples were collected over 24 h after dosing, and the PK parameters were calculated by noncompartment analysis. All available data of the subjects who received LCB01-0371 at least once were included in the safety data summaries.Results: In the fed condition, both the maximum plasma concentration (Cmax) and the total systemic exposure (area under the plasma concentration–time curve from time zero to the last observed time point [AUClast]) decreased by ~33% and 10%, respectively. The time to reach Cmax was delayed by ~1.25 h in the fed condition, whereas the mean elimination half-life remained similar in both conditions. In the fed/fasting condition, the geometric mean ratios and 90% CI of the Cmax and AUClast were 0.666 (0.470–0.945) and 0.897 (0.761–1.057), respectively. There were no drug-related adverse events (AEs) or serious AEs.Conclusion: Although the Tmax after a single oral 800 mg dose of LCB01-0371 was slightly delayed under the fed condition compared to the fasting condition, the total systemic exposure was similar under both conditions. Therefore, LCB01-0371 could be administered regardless of food intake. Keywords: antibiotic resistance, gram-positive bacteria, clinical trial
first_indexed 2024-12-11T06:33:58Z
format Article
id doaj.art-521d14d2615d465993a9e379ae76228b
institution Directory Open Access Journal
issn 1177-8881
language English
last_indexed 2024-12-11T06:33:58Z
publishDate 2018-06-01
publisher Dove Medical Press
record_format Article
series Drug Design, Development and Therapy
spelling doaj.art-521d14d2615d465993a9e379ae76228b2022-12-22T01:17:26ZengDove Medical PressDrug Design, Development and Therapy1177-88812018-06-01Volume 121707171438756Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibioticSunwoo JKim YKChoi YYu KSNam HCho YLYoon SChung JYJung Sunwoo,1 Yu Kyong Kim,1 Yewon Choi,1 Kyung-Sang Yu,1 Heesook Nam,2 Young Lag Cho,2 Seonghae Yoon,3 Jae-Yong Chung3 1Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, 2LegoChem Biosciences, Inc., Daejeon, 3Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Bundang Hospital, Seongnam, Republic of Korea Background: LCB01-0371 is a novel oxazolidinone antibiotic that blocks protein production by binding to bacterial 23S ribosomes. This antibiotic is active against Gram-positive bacteria. This study aimed to evaluate the effect of food on the pharmacokinetics (PKs) of LCB01-0371 and evaluate its safety profile.Subjects and methods: A randomized, open-label, two-way crossover study was performed in 18 healthy Korean male subjects. All subjects received a single oral 800 mg dose of LCB01-0371 in each period under fed or fasting condition with a 7-day washout in between. The fed condition was defined as consumption of a meal of 800–1,000 kcal containing ~50% of fat content. Serial blood samples were collected over 24 h after dosing, and the PK parameters were calculated by noncompartment analysis. All available data of the subjects who received LCB01-0371 at least once were included in the safety data summaries.Results: In the fed condition, both the maximum plasma concentration (Cmax) and the total systemic exposure (area under the plasma concentration–time curve from time zero to the last observed time point [AUClast]) decreased by ~33% and 10%, respectively. The time to reach Cmax was delayed by ~1.25 h in the fed condition, whereas the mean elimination half-life remained similar in both conditions. In the fed/fasting condition, the geometric mean ratios and 90% CI of the Cmax and AUClast were 0.666 (0.470–0.945) and 0.897 (0.761–1.057), respectively. There were no drug-related adverse events (AEs) or serious AEs.Conclusion: Although the Tmax after a single oral 800 mg dose of LCB01-0371 was slightly delayed under the fed condition compared to the fasting condition, the total systemic exposure was similar under both conditions. Therefore, LCB01-0371 could be administered regardless of food intake. Keywords: antibiotic resistance, gram-positive bacteria, clinical trialhttps://www.dovepress.com/effect-of-food-on-the-pharmacokinetic-characteristics-of-a-single-oral-peer-reviewed-article-DDDTfood effectpharmacokineticsoxazolidinonenovel antibiotic
spellingShingle Sunwoo J
Kim YK
Choi Y
Yu KS
Nam H
Cho YL
Yoon S
Chung JY
Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic
Drug Design, Development and Therapy
food effect
pharmacokinetics
oxazolidinone
novel antibiotic
title Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic
title_full Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic
title_fullStr Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic
title_full_unstemmed Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic
title_short Effect of food on the pharmacokinetic characteristics of a single oral dose of LCB01-0371, a novel oxazolidinone antibiotic
title_sort effect of food on the pharmacokinetic characteristics of a single oral dose of lcb01 0371 a novel oxazolidinone antibiotic
topic food effect
pharmacokinetics
oxazolidinone
novel antibiotic
url https://www.dovepress.com/effect-of-food-on-the-pharmacokinetic-characteristics-of-a-single-oral-peer-reviewed-article-DDDT
work_keys_str_mv AT sunwooj effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic
AT kimyk effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic
AT choiy effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic
AT yuks effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic
AT namh effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic
AT choyl effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic
AT yoons effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic
AT chungjy effectoffoodonthepharmacokineticcharacteristicsofasingleoraldoseoflcb010371anoveloxazolidinoneantibiotic